arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Neuronetics, Inc.

STIM
$2.38 ▲ +0.12 (+5.09%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
39 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuronetics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $165.6M
Dividend Yield
Revenue Growth 7.8%
Op. Margin -26.1%
ROIC -9.5%
FCF / Share $-0.14
Trailing P/E
Price / Book 12.5x
FCF Yield
Debt / Equity 4.62
info Valuation on last close. End-of-day price, Aug 7, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.45M
↑ +7.8%
Net Income Profit after all expenses
$-10.79M
↑ +14.9%
Operating Margin Operating profit as % of sales
-26.1%
↓ -116.3% 10th
FCF / Share Free cash flow per share
$-0.14
↑ +51.0%
Long-Term Debt Long-term obligations
$61.30M
↓ -6.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
4
Financial Health
23
Cash Quality
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters